IL22 and rheumatoid arthritis: Research has shown that sulforaphane treatment (10 μΜ), in addition to decreased expression of the transcription factor RORγt, as well as IL-17A, IL-17F, and IL-22, also induces a pro-oxidative state in untransformed human T-cells of healthy donors or RA patients translated as an increase in intracellular reactive oxygen species (ROS) and a marked decrease in glutathione (GSH).